Andrographolide impairs alpha-naphthylisothiocyanate-induced cholestatic liver injury in vivo

To investigate if andrographolide impairs cholestatic liver injury. All rats were randomly divided into six groups—(1) control ( n  = 6), (2) control + 200 mg/kg andrographolide ( n  = 6), (3) alpha-naphthylisothiocyanate (ANIT)-control ( n  = 6), (4) ANIT + 50 mg/kg andrographolide ( n  = 6), (5) ANIT + 100 mg/kg andrographolide ( n  = 6), and (6) ANIT + 200 mg/kg andrographolide ( n  = 6). We gavaged 50 mg/kg ANIT to mimic cholestatic liver injury in rats. Seven days after treatment, all the rats were killed. Serum biochemistry and hepatic histopathological assays were performed to evaluate liver injury. We observed that 200 mg/kg andrographolide significantly decreased the level of alanine transaminase, aspartate aminotransferase, alkaline phosphatase, γ-glutamyltranspeptidase, total bilirubin, and total bile acid in the blood. It also markedly decreased hepatic interleukin-6 and tumor necrosis factor α. Furthermore, 200 mg/kg andrographolide significantly decreased malondialdehyde but increased superoxide dismutase, glutathione, and erythrocyte glutathione peroxidase. Moreover, 200 mg/kg andrographolide effectively increased the accumulation of sirtuin 1 and nuclear erythroid 2-related factor-2. It also attenuated the level of nuclear factor kappa-light-chain-enhancer of activated B and cyclooxygenase-2. These data suggest that andrographolide may impair cholestatic liver injury via anti-inflammatory and anti-oxidative stress.